Skip to main content
SpringerLink
Log in

A North Central Cancer Treatment Group Phase II Trial of Topotecan in Relapsed Gliomas

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Current systemic treatment options for patientswith relapsed gliomas are limited. Thetopoisomerase I inhibitor topotecan has demonstrated broadantitumor activity in both preclinicalstudies as well as a number of phase I and II trials in humans.Studies in primates have shown goodcerebrospinal fluid levels of topotecan following systemicadministration. We therefore performed this phase II trial in patients who developed evidence of progressive glioma after definitive radiation therapy. Patients were treated with 1.5mg/m2 intravenously daily for 5 consecutive days repeatedevery three weeks. For patients who had received priornitrosourea-containing chemotherapy, thestarting dose was 1.25 mg/m2. Thirty-three patients wereentered on this study. All patients wereeligible and evaluable for both response and toxicity. Sevenpatients experienced grade 4 leukopeniawith 2 of these patients dying of infection-relatedcomplications. Six of these seven patients werenot taking anticonvulsants during treatment. Nine patientsdeveloped grade 3-4 thrombocytopenia,seven of whom were not taking anticonvulsants. Nonhematologicside effects were infrequent andmanageable. One patient experienced a partial response to thistreatment for an overall response rateof 3% (95% binomial confidence interval 0.3%-20.4%). The median time to progression was 14.9weeks and median survival 19.9 weeks. Topotecan at this dose andschedule showed no substantial activity in relapsed gliomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Walker MD, Alexander E, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA: Evaluation BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49: 333–343, 1978

    Google Scholar 

  2. Kristiansen K, Hagen S, Kollevold T, Torvik A, Holme I, Nesbakken R, Hatlevoll R, Lindgren M, Brun A, Lingren S, Notter G, Andersen AP, Elgen K: Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 47: 649–652, 1981

    Google Scholar 

  3. Shaw EG, Daumas-Duport C, Scheithauer BW, Gilbertson DT, O'Fallon JR, Earle JD, Laws ER, Okazaki H: Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg 70: 853–861, 1989

    Google Scholar 

  4. Karim ABMF, Maat B, Hatlevoll R, Menten J, Rutten EHJM, Thomas DGT, Mascarenhas F, Horiot JC, Parvinen LM, van-Reijn M, Jager JJ, Fabrini MG, vanAlphen AM, Hamers HP, Gaspar L, Noordman E, Pierart M, vanGlabbeke M: A randomized trial on dose-response in radiation therapy of lowgrade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys 36: 549–556, 1996

    Google Scholar 

  5. Walker MD, Green SB, Byar DP, Alexander E, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, Owens G, Ransohoff J, Roberstson JT, Shapiro WR, Smith KR, Wilson CB, Strike TA: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. New Engl J Med 303: 1323–1329, 1980

    Google Scholar 

  6. Yung WKA: Chemotherapy for malignant brain tumors. Curr Opin Oncol 2: 673–678, 1990

    Google Scholar 

  7. Eck SL, Alavi JB, Alavi A, Davis A, Hackney D, Judy K, Mollman J, Phillips PC, Wheeldon EB, Wilson JM: Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. Human Gene Therapy 7: 1465–1482, 1996

    Google Scholar 

  8. Walter KA, Tamargo RJ, Olivi A, Burger PC, Brem H: Intratumoral chemotherapy. Neurosurg 37: 1129–1145, 1995

    Google Scholar 

  9. Potmesil M: Camptothecins: from bench research to hospital wards. Cancer Res 54: 1431–1439, 1994

    Google Scholar 

  10. Slichemyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH: The current status of camptothecin analogues as antitumor agents. J Nat Cancer Inst 85: 271–291, 1993

    Google Scholar 

  11. Lynch T: Topotecan today. J Clin Oncol 14: 3053–3055, 1996

    Google Scholar 

  12. Blaney SM, Cole DE, Balis FM, Godwin K, Poplack DG: Plasma and cerebrospinal pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 53: 725–727, 1993

    Google Scholar 

  13. Jennison C, Tumbull BW: Confidence interval for a binomial parameter following a multistage test with application MILSTD 105D and medical trials. Technometrics 25: 49–58, 1983

    Google Scholar 

  14. Houghton PJ, Cheshire PJ, Hallman JD, Lutz L, Freidinan HS, Danks MK, Houghton JA: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36: 393–403, 1995

    Google Scholar 

  15. Hare CB, Elion GB, Houghton PJ, Houghton JA, Keir S, Marcelli SL, Bigner DD, Friedman HS: Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 39: 187–191, 1997

    Google Scholar 

  16. Friedman HS, Houghton PJ: Treatment of central nervous system xenografts with camptothecins. Ann NY Acad Sci 803: 210–212, 1996

    Google Scholar 

  17. Pottnesil M, Vardeman D, Kozielski AJ, Mendoza J, Stehlin JS, Giovanella BC: Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models. Cancer Res 55: 5637–5641, 1995

    Google Scholar 

  18. Rajkurnar SV, Burch PA, Nair S, Dinapoli RP, Scheithauer B, O'Fallon JR, Etzell PS, Leitch JM, Morton RF, Marks RS: Phase II study of 2-chlorodcoxyadenosine in patients with recurrent glioma. Am J Clin Oncol (in press)

  19. Cascino TL, Veeder MH, Buckner X, O'Fallon JR, Wiesenfeld M, Levitt R, Goldberg RM, Kuross SA, Morton RF, Scheithauer BW: Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor. J Neuro-Oncol 30: 243–246, 1996

    Google Scholar 

  20. Curran WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach J, Chang CH, Rotman M, Asbell SO, Krisch RE, Nelson DF: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Nat Cancer Inst 85: 704–710, 1993

    Google Scholar 

  21. Macdonald D, Cairricross G, Stewart D, Forsyth P, Sawka C, Wainman N, Eisenhauer E for the National Cancer Institute of Canada Clinical Trials Group (NCIC CW): Phase II study of topotecan in patients with recurrent malignant glioma. Ann Oncol 7: 205–207, 1996

    Google Scholar 

  22. Blaney SM, Phillips PC, Packer RJ, Heideman RL, Berg SL, Adamson PC, Allen X, Sallan SE, Jakacki RI, Lange IB, Reaman GH, Horowitz ME, Poplack DG, Balis FM: Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 78: 527–531, 1996

    Google Scholar 

  23. Kyritsis A, Newlands ES, Brock CS, Gleason M, Jaeckle K, Levin V, Mower M, Evans H, Dane G, DeWitte M, Yung W: Phase II trial of topotecan as a continuous intravenous infusion in patients with high-grade glioma. Proc Am Soc Clin Oncol 16: 394a, 1997

    Google Scholar 

  24. Friedman HS, Kerby T, Fields, Zilsch JE, Graden D, McLendon RE, Houghton PJ, Arbuck S, Cokgor I, Friedman AH: Topotecan treatment of adults with primary malignant glioma. Cancer 85, 1160–1165, 1999

    Google Scholar 

  25. Grossman SA, Hochberg F, Fisher J, Chen TL, Kim L, Gregory R, Gochow LB, Piantadosi S: Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. Cancer Chemother Pharmacol 42: 118–126, 1998

    Google Scholar 

  26. Friedman HS, Petros WP, Friedman AJ, Schaaf LF, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provensale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL: Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17: 1516–1525, 1999

    Google Scholar 

  27. Reid J, Buckner J, Schaaf L, Novotny P, Wright K, Kimmel D, Miller L: Pharmacokinetics of irinotecan (CPT-11) in recurrent glioma patients: results of an NCCTG phase II trial. Proceedings ASCO 18: 141, 1999

    Google Scholar 

  28. Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB: Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 12: 1946–1954, 1994

    Google Scholar 

  29. Zamboni WC, Gajjar AJ, Heideman RL, Beijnen JH, Rosing H, Houghton PJ, Stewart CF: Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 4: 783–789, 1998

    Google Scholar 

  30. Straathof CSM, van den Bent MJ, Loos WJ, Vecht CJ, Schellens JHM: The accumulation of topotecan in 9L, glioma and in brain parenchyma with and without dexamethasone administration. J Neuro-Oncol 42: 117–122, 1999

    Google Scholar 

  31. Hochberg F, Grossman SA, Mikkelsen T, Calabresi P, Fisher J, Piantadosi S: Efficacy of 9-aminocamptothecin in adults with newly diagnosed glioblastoma multiforme and recurrent high grade astrocytomas. Proceedings ASCO 17: 1494, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mayo Clinic and Mayo Foundation, Rochester, MN

    Patrick A. Burch, Terrence L. Cascino, Bernd W. Scheithauer, Paul Novotny & Jan C. Buckner

  2. Geisinger Clinic & Medical Center CCOP, Danville, PA

    Albert M. Bernath & Suresh Nair

  3. Quain and Ramstad Clinic, Bismarck, ND

    Delano M. Pfeifle

  4. Illinois Oncology Research Assn. CCOP, Peoria, IL

    John W. Kugler

  5. Sioux Community Cancer Consortium, Sioux Falls, SD, USA

    Loren K. Tschetter

Authors
  1. Patrick A. Burch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Albert M. Bernath
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Terrence L. Cascino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bernd W. Scheithauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paul Novotny
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Suresh Nair
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jan C. Buckner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Delano M. Pfeifle
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. John W. Kugler
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Loren K. Tschetter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burch, P.A., Bernath, A.M., Cascino, T.L. et al. A North Central Cancer Treatment Group Phase II Trial of Topotecan in Relapsed Gliomas. Invest New Drugs 18, 275–280 (2000). https://doi.org/10.1023/A:1006438109266

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006438109266

Search

Navigation